Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.
The group highlights its ambitions in cancer again, but is at least two years away from launching a new product.
Evaluate Vantage's coverage of the Ash 2021 congress.
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Evorpacept adds a solid tumour setback to last week’s disappointment in blood cancers, and the CD47 bubble deflates.
The early movers could point to a disappointing meeting.
The latest deal over a CD47 asset has got investors wondering who could be next.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.